Britain and America have finalized a landmark trade agreement that will keep zero levies on British drug products going into the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to boost funding on pharmaceuticals through the NHS. This move secures that import taxes on these vital exports will be held at nothing for a duration of three years.
This deal is in response to recent threats to significantly raise duties on branded pharmaceutical products, with increases discussed as high as double the cost.
"This deal between the United Kingdom strengthens the global environment for cutting-edge drugs and establishes much-needed equity to U.S.–U.K. medicine commerce," an announcement declared.
Economic Significance
Drugs are one of the the United Kingdom's most significant goods shipped to the US, which is by far the biggest destination for leading companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period leading up to last September, the UK shipped medicines totaling £11.1bn to the US. This amount made up 17.4% of British export trade in that period.
"This guarantee secures employment, increases funding and facilitates the UK to emerge as a global hub for medical research," a government official remarked.
Key UK Commitments
The deal involves several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must pay back to the NHS to control costs will be limited at 15%. Previously, repayments topped twenty percent.
Recent Tensions
The pact comes amid a long-running dispute between the sector and the ministers over drug pricing and NHS adoption.
This friction were exacerbated by assertions that American patients were paying a premium for the equivalent treatments than people in the other developed nations.
In recent months, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure stated that the NHS needed to spend more on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the past decade.
